Antioxidants: Natural Antibiotics

The aim of this current piece of writing is to draw the attention of readers and researchers toward the natural antioxidants that can take the place of synthetic antibiotics to avoid bacterial resistance and gastrotoxicity/nephrotoxicity. Antioxidants such as polyphenols, vitamins, and carotenoids are the organic compounds mainly extracted from natural sources and dominantly involved in boosting the defense system of organisms. The main public health-related issue over the globe is ever-growing bacterial resistance to synthetic antibiotics, which is being continuously reported during the last decade. Further, the pipeline of the development of new synthetic antibacterial agents to replace the resistant antibiotics in clinical set-up is gradually drying up. This scenario originated the concept to revive the interest toward natural antibacterial products due to their chemical diversity, which provide important therapeutic effect and make the microbes unable to copy them for creating resistance. Natural products, especially polyphenols had been seen in antioxidant, antibacterial, anticancer, anti-inflammation, and antiviral activities with encouraging results. In this chapter, we will focus over the role of natural antioxidants as antibacterial agents

Fingerprinting Technique for YouTube Videos Identification in Network Traffic

Recently, many video streaming services, such as YouTube, Twitch, and Facebook, have contributed to video streaming traffic, leading to the possibility of streaming unwanted and inappropriate content to minors or individuals at workplaces. Therefore, monitoring such content is necessary. Although the video traffic is encrypted, several studies have proposed techniques using traffic data to decipher users’ activity on the web. Dynamic Adaptive Streaming over HTTP (DASH) uses Variable Bit-Rate (VBR) - the most widely adopted video streaming technology, to ensure smooth streaming. VBR causes inconsistencies in video identification in most research. This research proposes a fingerprinting method to accommodate for VBR inconsistencies. First, bytes per second (BPS) are extracted from the YouTube video stream. Bytes per Period (BPP) are generated from the BPS, and then fingerprints are generated from these BPPs. Furthermore, a Convolutional Neural Network (CNN) is optimized through experiments. The resulting CNN is used to detect YouTube streams over VPN, Non-VPN, and a combination of both VPN and Non-VPN network traffic

Microencapsulation of microbial antioxidants from Mucor circinelloides, their physico-chemical characterization, in vitro digestion and releasing behaviors in food

This study aimed at increasing the stability of heat-labile and pH-sensitive microbial antioxidants by the microencapsulation. Microbial antioxidants from Mucor circinelloides were microencapsulated. The physico-chemical and powder flowing properties of resulting microcapsules were evaluated. The initial safety studies were evaluated by in vivo acute oral toxicity tests. The bio-accessibility of powders vs. extracts was analyzed in in vitro digestion models with further application of microcapsules to model food system. Physico-chemical properties were significantly different (p 0.05) in powder flowing properties. The microencapsulation of extract with 5% whey protein hydrogels (WPHG) + 5% pectin (T) showed higher retain-ability of polyphenols accompanying low degradation in gastric and intestinal digestion and with no major toxicity signs. The addition of T microcapsule did not produce any nutritional, physico-chemical, compositional, and nutritional distinctions in cheese. Microencapsulation proved to be appropriate approach for not only protecting the thermo-labile and pH-sensitive microbial antioxidants but also for enhanced bioavailability, and targeted release of bioactive extracts

Design Project for Production of IFN-alpha (semester?), IPRO 345

The IPRO goal was to design a process for the production of the biotherapeutic compound IFN-Alpha from Chinese Hamster ovaries. After the process design was complete, a process flow diagram showing the actual process and separation steps was created and finally an economic analysis of the market feasibility of the product was prepared. The approach to the IPRO involved dividing the objectives into three major groups: (1) the Che 496 group was involved in the process design and the separation processes; (2) the Che 296 group was involved in the public perception of biotechnology, the useful products from biotechnology and the survey of the commercial biotherapeutic compounds; and (3) the 435 group was involved with the history of biotherapeutics, classification and actions infernos and the companies involved in the production of therapeutics. The individual members of these groups are seen on the team list below.Deliverables for IPRO 345: Design Project for Production of IFN-alpha for the Spring 2006 semeste

Design Project for Production of IFN-alpha (semester?), IPRO 345: IFN-alpha Production IPRO 345 Poster Sp06

The IPRO goal was to design a process for the production of the biotherapeutic compound IFN-Alpha from Chinese Hamster ovaries. After the process design was complete, a process flow diagram showing the actual process and separation steps was created and finally an economic analysis of the market feasibility of the product was prepared. The approach to the IPRO involved dividing the objectives into three major groups: (1) the Che 496 group was involved in the process design and the separation processes; (2) the Che 296 group was involved in the public perception of biotechnology, the useful products from biotechnology and the survey of the commercial biotherapeutic compounds; and (3) the 435 group was involved with the history of biotherapeutics, classification and actions infernos and the companies involved in the production of therapeutics. The individual members of these groups are seen on the team list below.Deliverables for IPRO 345: Design Project for Production of IFN-alpha for the Spring 2006 semeste

Design Project for Production of IFN-alpha (semester?), IPRO 345: IFN-alpha Production IPRO 345 Abstract Sp06

The IPRO goal was to design a process for the production of the biotherapeutic compound IFN-Alpha from Chinese Hamster ovaries. After the process design was complete, a process flow diagram showing the actual process and separation steps was created and finally an economic analysis of the market feasibility of the product was prepared. The approach to the IPRO involved dividing the objectives into three major groups: (1) the Che 496 group was involved in the process design and the separation processes; (2) the Che 296 group was involved in the public perception of biotechnology, the useful products from biotechnology and the survey of the commercial biotherapeutic compounds; and (3) the 435 group was involved with the history of biotherapeutics, classification and actions infernos and the companies involved in the production of therapeutics. The individual members of these groups are seen on the team list below.Deliverables for IPRO 345: Design Project for Production of IFN-alpha for the Spring 2006 semeste

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo